IKT - Inhibikase Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 19.88M
Enterprise value -2.82M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.94
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.16

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3-25.29%
S&P500 52-week change 32.74%
52-week high 31.2100
52-week low 30.4400
50-day moving average 30.6192
200-day moving average 30.6992

Share statistics

Avg vol (3-month) 3306.95k
Avg vol (10-day) 364.93k
Shares outstanding 531.06M
Implied shares outstanding 6N/A
Float 822.71M
% held by insiders 124.63%
% held by institutions 120.06%
Shares short (14 May 2023) 4348.54k
Short ratio (14 May 2023) 42.07
Short % of float (14 May 2023) 41.36%
Short % of shares outstanding (14 May 2023) 41.12%
Shares short (prior month 13 Apr 2023) 4264.1k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)-12,825.31%

Management effectiveness

Return on assets (ttm)-34.19%
Return on equity (ttm)-60.31%

Income statement

Revenue (ttm)141.93k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)40.20%
Gross profit (ttm)N/A
Net income avi to common (ttm)-17.89M
Diluted EPS (ttm)-0.7800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)25.72M
Total cash per share (mrq)0.83
Total debt (mrq)325.01k
Total debt/equity (mrq)1.28
Current ratio (mrq)10.37
Book value per share (mrq)0.81

Cash flow statement

Operating cash flow (ttm)-19.39M
Levered free cash flow (ttm)-13.15M